Fortress Biotech, Inc. (FBIO)
| Market Cap | 43.27M |
| Revenue (ttm) | 81.50M |
| Net Income (ttm) | -50.25M |
| Shares Out | 27.56M |
| EPS (ttm) | -3.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 376,835 |
| Open | 1.600 |
| Previous Close | 1.590 |
| Day's Range | 1.550 - 1.615 |
| 52-Week Range | 1.360 - 4.430 |
| Beta | 1.75 |
| Analysts | Strong Buy |
| Price Target | 17.00 (+982.8%) |
| Earnings Date | Nov 14, 2024 |
About FBIO
Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and ... [Read more]
Financial Performance
In 2023, Fortress Biotech's revenue was $84.51 million, an increase of 11.58% compared to the previous year's $75.74 million. Losses were -$68.67 million, -27.42% less than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for FBIO stock is "Strong Buy." The 12-month stock price forecast is $17.0, which is an increase of 982.80% from the latest price.
News
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally adv...
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint...
Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
U.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of 2025
Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
Journey Medical to host investor conference call on Monday, November 4, 2024, at 8:30 a.m. E.T. Journey Medical to host investor conference call on Monday, November 4, 2024, at 8:30 a.m. E.T.
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference
Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral Doxycycline 40 mg Capsules (Oracea®) in Healthy Subject...
Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
SCOTTSDALE, Ariz., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses o...
Fortress Biotech to Participate in October 2024 Investor Conferences
MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term val...
Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements
MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance ...
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28, 2024 Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28,...
Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference
SCOTTSDALE, Ariz., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses ...
Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term val...
Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
SCOTTSDALE, Ariz., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses ...
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
WALTHAM, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James...
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults
Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
New Drug Application for DFD-29 to treat rosacea under FDA review; PDUFA goal date of November 4, 2024 Total revenues for the second quarter ended June 30, 2024 were $14.9 million, a 14% increase from...
Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates
WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial r...
Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024
Company to host conference call to discuss financial results and provide a corporate update on August 12, 2024 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide ...
Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027
Extends maturity of long-term debt as Fortress‘ late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a four...
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U....
GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research
YONGIN, South Korea and WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- GC Cell (KRX: 144510.KS) and Checkpoint Therapeutics ("Checkpoint") (Nasdaq: CKPT) have announced a collaboration to explore t...
Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors
SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and mar...
Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
MIAMI, July 05, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO; FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-te...
Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has ente...
Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has comp...
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has reac...